Investigation of 5'-Norcarbocyclic Nucleoside Analogues as Antiprotozoal and Antibacterial Agents.

Clicks: 341
ID: 63585
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #200 of 729 articles by views in molecules

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 729 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Carbocyclic nucleosides have long played a role in antiviral, antiparasitic, and antibacterial therapies. Recent results from our laboratories from two structurally related scaffolds have shown promising activity against both and several parasitic strains. As a result, a small structure activity relationship study was designed to further probe their activity and potential. Their synthesis and the results of the subsequent biological activity are reported herein.
Reference Key
khandazhinskaya2019investigationmolecules Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Khandazhinskaya, Anastasia L;Matyugina, Elena S;Solyev, Pavel N;Wilkinson, Maggie;Buckheit, Karen W;Buckheit, Robert W;Chernousova, Larisa N;Smirnova, Tatiana G;Andreevskaya, Sofya N;Alzahrani, Khalid J;Natto, Manal J;Kochetkov, Sergey N;de Koning, Harry P;Seley-Radtke, Katherine L;
Journal molecules
Year 2019
DOI
E3433
URL
Keywords
tuberculosis antiparasitic nucleosides carbocyclic leishmanial mycobacterial

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.